Joel Kramer, PsyD

Neuropsychologist

Joel Kramer is a neuropsychologist and director of the neuropsychology program at the UCSF Memory and Aging Center where he helps diagnose and care for patients with a wide range of memory disorders. In his research, Kramer studies the cognitive and behavioral effects of neurodegenerative disease, behavioral markers of pre-clinical Alzheimer's disease, and cognitive changes associated with typical aging.

Kramer earned a doctorate in psychology at Baylor University in Waco, Texas and completed a postdoctoral fellowship at the Veteran's Administration Clinic in Martinez. He is board certified in clinical neuropsychology. Kramer is a clinical professor of neuropsychology in Neurology at UCSF.

Clinics

Memory and Aging Center
1500 Owens St., Suite 320
San Francisco, CA 94158
Phone: (415) 353-2057
Fax: (415) 353-8292

Hours: Monday to Friday
8 a.m. – 5 p.m.

Conditions & Treatments

Academic Title

Professor

More about Joel Kramer

Education

Baylor University School of Medicine 1982

Residencies

Veterans Affairs Medical Center, Martinez, Calif., Neuropsychology 1983

Selected Research and Publications

  1. Seo SW, Thibodeau MP, Perry DC, Hua A, Sidhu M, Sible I, Vargas JNS, Gaus SE, Rabinovici GD, Rankin KD, Boxer AL, Kramer JH, Rosen HJ, Gorno-Tempini ML, Grinberg LT, Huang EJ, DeArmond SJ, Trojanowski JQ, Miller BL, Seeley WW. Early vs late age at onset frontotemporal dementia and frontotemporal lobar degeneration. Neurology. 2018 Mar 20; 90(12):e1047-e1056.
  2. Staffaroni AM, Brown JA, Casaletto KB, Elahi FM, Deng J, Neuhaus J, Cobigo Y, Mumford PS, Walters S, Saloner R, Karydas A, Coppola G, Rosen HJ, Miller BL, Seeley WW, Kramer JH. The Longitudinal Trajectory of Default Mode Network Connectivity in Healthy Older Adults Varies As a Function of Age and Is Associated with Changes in Episodic Memory and Processing Speed. J Neurosci. 2018 Mar 14; 38(11):2809-2817.
  3. Winer JR, Maass A, Pressman P, Stiver J, Schonhaut DR, Baker SL, Kramer J, Rabinovici GD, Jagust WJ. Associations Between Tau, -Amyloid, and Cognition in Parkinson Disease. JAMA Neurol. 2018 Feb 01; 75(2):227-235.
  4. Bodien YG, McCrea M, Dikmen S, Temkin N, Boase K, Machamer J, Taylor SR, Sherer M, Levin H, Kramer JH, Corrigan JD, McAllister TW, Whyte J, Manley GT, Giacino JT. Optimizing Outcome Assessment in Multicenter TBI Trials: Perspectives From TRACK-TBI and the TBI Endpoints Development Initiative. J Head Trauma Rehabil. 2018 Jan 30.
  5. Rojas JC, Stephens ML, Rabinovici GD, Kramer JH, Miller BL, Seeley WW. Multiproteinopathy, neurodegeneration and old age: a case study. Neurocase. 2018 Feb; 24(1):1-6.
  6. Bettcher BM, Johnson SC, Fitch R, Casaletto KB, Heffernan KS, Asthana S, Zetterberg H, Blennow K, Carlsson CM, Neuhaus J, Bendlin BB, Kramer JH. Cerebrospinal Fluid and Plasma Levels of Inflammation Differentially Relate to CNS Markers of Alzheimer's Disease Pathology and Neuronal Damage. J Alzheimers Dis. 2018; 62(1):385-397.
  7. Weintraub S, Besser L, Dodge HH, Teylan M, Ferris S, Goldstein FC, Giordani B, Kramer J, Loewenstein D, Marson D, Mungas D, Salmon D, Welsh-Bohmer K, Zhou XH, Shirk SD, Atri A, Kukull WA, Phelps C, Morris JC. Version 3 of the Alzheimer Disease Centers' Neuropsychological Test Battery in the Uniform Data Set (UDS). Alzheimer Dis Assoc Disord. 2018 Jan-Mar; 32(1):10-17.
  8. Perry DC, Brown JA, Possin KL, Datta S, Trujillo A, Radke A, Karydas A, Kornak J, Sias AC, Rabinovici GD, Gorno-Tempini ML, Boxer AL, De May M, Rankin KP, Sturm VE, Lee SE, Matthews BR, Kao AW, Vossel KA, Tartaglia MC, Miller ZA, Seo SW, Sidhu M, Gaus SE, Nana AL, Vargas JNS, Hwang JL, Ossenkoppele R, Brown AB, Huang EJ, Coppola G, Rosen HJ, Geschwind D, Trojanowski JQ, Grinberg LT, Kramer JH, Miller BL, Seeley WW. Clinicopathological correlations in behavioural variant frontotemporal dementia. Brain. 2017 Dec 01; 140(12):3329-3345.
  9. Perry DC, Datta S, Sturm VE, Wood KA, Zakrzewski J, Seeley WW, Miller BL, Kramer JH, Rosen HJ. Reward deficits in behavioural variant frontotemporal dementia include insensitivity to negative stimuli. Brain. 2017 Dec 01; 140(12):3346-3356.
  10. Bejanin A, Schonhaut DR, La Joie R, Kramer JH, Baker SL, Sosa N, Ayakta N, Cantwell A, Janabi M, Lauriola M, O'Neil JP, Gorno-Tempini ML, Miller ZA, Rosen HJ, Miller BL, Jagust WJ, Rabinovici GD. Tau pathology and neurodegeneration contribute to cognitive impairment in Alzheimer's disease. Brain. 2017 Dec 01; 140(12):3286-3300.
  11. Clifford KM, Samboju V, Cobigo Y, Milanini B, Marx GA, Hellmuth JM, Rosen HJ, Kramer JH, Allen IE, Valcour VG. Progressive Brain Atrophy Despite Persistent Viral Suppression in HIV Patients Older Than 60 Years. J Acquir Immune Defic Syndr. 2017 11 01; 76(3):289-297.
  12. Walsh CM, Ruoff L, Walker K, Emery A, Varbel J, Karageorgiou E, Luong PN, Mance I, Heuer HW, Boxer AL, Grinberg LT, Kramer JH, Miller BL, Neylan TC. Sleepless Night and Day, the Plight of Progressive Supranuclear Palsy. Sleep. 2017 Nov 01; 40(11).
  13. Watson CL, Possin K, Allen IE, Hubbard HI, Meyer M, Welch AE, Rabinovici GD, Rosen H, Rankin KP, Miller Z, Santos-Santos MA, Kramer JH, Miller BL, Gorno-Tempini ML. Visuospatial Functioning in the Primary Progressive Aphasias. J Int Neuropsychol Soc. 2018 Mar; 24(3):259-268.
  14. Schonhaut DR, McMillan CT, Spina S, Dickerson BC, Siderowf A, Devous MD, Tsai R, Winer J, Russell DS, Litvan I, Roberson ED, Seeley WW, Grinberg LT, Kramer JH, Miller BL, Pressman P, Nasrallah I, Baker SL, Gomperts SN, Johnson KA, Grossman M, Jagust WJ, Boxer AL, Rabinovici GD. 18 F-flortaucipir tau positron emission tomography distinguishes established progressive supranuclear palsy from controls and Parkinson disease: A multicenter study. Ann Neurol. 2017 Oct; 82(4):622-634.
  15. Leung JM, Sands LP, Chen N, Ames C, Berven S, Bozic K, Burch S, Chou D, Covinsky K, Deviren V, Kinjo S, Kramer JH, Ries M, Tay B, Vail T, Weinstein P, Chang S, Meckler G, Newman S, Tsai T, Voss V, Youngblom E. Perioperative Gabapentin Does Not Reduce Postoperative Delirium in Older Surgical Patients: A Randomized Clinical Trial. Anesthesiology. 2017 10; 127(4):633-644.
  16. Iaccarino L, Tammewar G, Ayakta N, Baker SL, Bejanin A, Boxer AL, Gorno-Tempini ML, Janabi M, Kramer JH, Lazaris A, Lockhart SN, Miller BL, Miller ZA, O'Neil JP, Ossenkoppele R, Rosen HJ, Schonhaut DR, Jagust WJ, Rabinovici GD. Local and distant relationships between amyloid, tau and neurodegeneration in Alzheimer's Disease. Neuroimage Clin. 2018; 17:452-464.
  17. Casaletto KB, Elahi FM, Bettcher BM, Neuhaus J, Bendlin BB, Asthana S, Johnson SC, Yaffe K, Carlsson C, Blennow K, Zetterberg H, Kramer JH. Neurogranin, a synaptic protein, is associated with memory independent of Alzheimer biomarkers. Neurology. 2017 Oct 24; 89(17):1782-1788.
  18. Elahi FM, Marx G, Cobigo Y, Staffaroni AM, Kornak J, Tosun D, Boxer AL, Kramer JH, Miller BL, Rosen HJ. Longitudinal white matter change in frontotemporal dementia subtypes and sporadic late onset Alzheimer's disease. Neuroimage Clin. 2017; 16:595-603.
  19. Sturm VE, Perry DC, Wood K, Hua AY, Alcantar O, Datta S, Rankin KP, Rosen HJ, Miller BL, Kramer JH. Prosocial deficits in behavioral variant frontotemporal dementia relate to reward network atrophy. Brain Behav. 2017 Oct; 7(10):e00807.
  20. Brown JA, Hua AY, Trujllo A, Attygalle S, Binney RJ, Spina S, Lee SE, Kramer JH, Miller BL, Rosen HJ, Boxer AL, Seeley WW. Advancing functional dysconnectivity and atrophy in progressive supranuclear palsy. Neuroimage Clin. 2017; 16:564-574.

Publications are derived from MEDLINE/PubMed and provided by UCSF Profiles, a service of the Clinical & Translational Science Institute (CTSI) at UCSF. Researchers can make corrections and additions to their publications by logging on to UCSF Profiles.